Eyenovia, Inc. Announces Adjournment of 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meetin...
Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print delivery
technology, today announced that it adjourned its 2020 Annual
Meeting of Stockholders (the “Annual Meeting”) originally scheduled
to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at
9:00 a.m., EDT, to be conducted in a virtual-only format, via live
webcast (the “Adjourned Annual Meeting”).
Stockholders will not be able to physically attend
the Adjourned Annual Meeting in person. Stockholders at the close
of business on the record date, April 15, 2020, are entitled to
participate in the Adjourned Annual Meeting by means of remote
communication. Stockholders and their proxy holders may be deemed
present in person and will be able to listen to the Adjourned
Annual Meeting live, vote, and submit questions via means of remote
communication as set forth below.
To be admitted to the Adjourned Annual Meeting,
stockholders should visit
www.virtualshareholdermeeting.com/EYEN2020, and must enter the
16-digit voting control number found in the proxy materials
previously sent to stockholders. The Company encourages
stockholders to access the Adjourned Annual Meeting prior to the
start time. Online check-in will begin at 8:45 a.m., EDT.
Stockholders should allow ample time for check-in procedures. A
list of stockholders entitled to vote at the Adjourned Annual
Meeting will be available and open to examination during the
entirety of the Adjourned Annual Meeting in accordance with
Delaware law at www.virtualshareholdermeeting.com/EYEN2020. If
stockholders encounter any difficulties accessing the Adjourned
Annual Meeting during the check-in or meeting time, please call the
technical support number that will be available at
Please note that the proxy card and voting
instruction card included with previously-distributed proxy
materials will not be updated to reflect the adjournment from an
in-person meeting to a virtual-only meeting, and may continue to be
used to vote shares in connection with the Adjourned Annual
Meeting. For additional information regarding how stockholders may
access, vote, and participate in the virtual Adjourned Annual
Meeting, please refer to the Company’s supplemental proxy materials
filed today with the U.S. Securities and Exchange Commission.
Whether or not a stockholder plans to attend the
virtual-only Adjourned Annual Meeting, the Company urges each
stockholder to vote and submit his or her proxy in advance of the
meeting by one of the methods described in the proxy materials.
About EyenoviaEyenovia, Inc.
(NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical
company developing a pipeline of microdose therapeutics utilizing
its patented piezo-print delivery technology. Eyenovia’s pipeline
is currently focused on the late-stage development of microdosed
medications for presbyopia, myopia progression and mydriasis. For
more Information please visit www.eyenovia.com.
Company Contact:Eyenovia, Inc.John
GandolfoChief Financial Officerjgandolfo@eyenovia.com
Investor Contact:The Ruth
GroupTram Bui / Alexander LoboPhone:
Historical Stock Chart
From Dec 2020 to Jan 2021
Historical Stock Chart
From Jan 2020 to Jan 2021